Chiron Behring Gmbh & Co.

Behringwerke Aktiengesellschaft

Klaus-Dieter Hungerer

Horst Domdey

Bernd-Ulrich Von Specht

Bernhard Knapp

Michael Broker

Michael Br&ouml;ker

Hansjorg Ronneberger

Klaus-Dieter Bremecker

The present invention relates to a hybrid protein comprising the,outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the,outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by,to laboratory animals or man.

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa

A pharmaceutical which is for nasal administration and contains a high molecular weight active compound and a gel-forming agent and, where appropriate, auxiliaries is described. High molecular weight active compounds of this type are, in particular, immunogens or other pharmacologically effective substances. In addition, a process for the preparation of a pharmaceutical of this type and its use are described.

Pharmaceutical which can be administered nasally, a process for its

Growing community of inventors

Marburg, Germany

Klaus-Dieter Hungerer